Acute respiratory distress syndrome (ARDS) phenotyping
Clinically, the Berlin ARDS definition describes acute respiratory distress syndrome (ARDS) as acute hypoxaemic respiratory failure that is not fully explained by cardiac failure or fluid overload, that develops within 7 days of clinical recognition of a known risk factor, with bilateral radiographic opacities that are not fully explained by effusions, lobar/lung collapse, or nodules. Three risk strata were defined on the basis of the severity of hypoxaemia represented by the ratio of partial pressure of oxygen in arterial blood to inspired oxygen concentration (PaO2/FiO2 ratio), assessed at a minimum positive end-expiratory pressure (PEEP) of 5 cmH2O . Hospital mortality worsens with severity of hypoxaemia and thus grade of ARDS (from 35% in mild ARDS to 46% in severe ARDS) [1, 2].
The ARDS consensus definitions to date have mainly relied on feasible clinical criteria, which helps to group patients together for inclusion in clinical trials and for clinical management [1, 3]. This...
This independent research by Dr Manu Shankar-Hari is supported by the National Institute for Health Research Clinician Scientist Award (NIHR-CS-2016-16-011). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
Dr Shankar-Hari wrote the first draft of the manuscript. All authors contributed towards the critical revision of the manuscript for important intellectual content and confirm the integrity of the work.
Dr Shankar-Hari is supported by the National Institute for Health Research Clinician Scientist Award (CS-2016-16-011). Dr Fan is supported by a New Investigator Award from the Canadian Institutes of Health Research.
Compliance with ethical standards
Conflicts of interest
All authors declare that they do have any personal conflict of interest directly related to this manuscript.
- 1.ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, Ferguson ND, Caldwell E, Fan E, Camporota L, Slutsky AS (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA 307:2526–2533Google Scholar
- 2.Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A, LUNG SAFE Investigators, ESICM Trials Group (2016) Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA 315:788–800CrossRefPubMedGoogle Scholar
- 10.Calfee CS, Delucchi KL, Sinha P, Matthay MA, Hackett J, Shankar-Hari M, McDowell C, Laffey JG, O'Kane CM, McAuley DF, Irish Critical Care Trials Group (2018) Acute respiratory distress syndrome subphenotypes and differential response to simvastatin: secondary analysis of a randomised controlled trial. Lancet Respir Med 6:691–698CrossRefPubMedGoogle Scholar
- 13.Bos LD, Schouten LR, van Vught LA, Wiewel MA, Ong DSY, Cremer O, Artigas A, Martin-Loeches I, Hoogendijk AJ, van der Poll T, Horn J, Juffermans N, Calfee CS, Schultz MJ, MARS Consortium (2017) Identification and validation of distinct biological phenotypes in patients with acute respiratory distress syndrome by cluster analysis. Thorax 72:876–883CrossRefPubMedPubMedCentralGoogle Scholar